Gland Pharma (GLAND) | Stock Overview & Key Data
Gland Pharma Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹4,350.00 on August 9, 2021
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gland Pharma
GLAND
|
295.80B Large-cap | -1.82% | 18.29% | 37.34% | 32.35% | 28.86% | 33.88% | 124.19% | -26.40% | 24.33% | 24.33% | 24.33% |
|
Sun Pharmaceutical
SUNPHARMA
|
3.88T Large-cap | 0.96% | -3.84% | 1.28% | 0.50% | 4.93% | 7.10% | 82.23% | 170.41% | 143.23% | 656.74% | 2,541.29% |
|
Divi's Laboratories
DIVISLAB
|
1.69T Large-cap | 1.34% | -2.25% | 8.85% | 4.11% | 4.17% | -0.43% | 85.44% | 58.15% | 496.33% | 1,610.60% | 10,946.76% |
|
Torrent
TORNTPHARM
|
1.39T Large-cap | 2.12% | 2.23% | 5.56% | 19.07% | 17.04% | 40.54% | 146.00% | 215.51% | 578.42% | 2,737.14% | 10,046.95% |
|
Dr. Reddy's
DRREDDY
|
1.10T Large-cap | 0.31% | -4.28% | 0.20% | -0.09% | 2.08% | -6.39% | 29.74% | 20.69% | 112.36% | 310.53% | 902.28% |
|
Lupin
LUPIN
|
1.07T Large-cap | 0.83% | -0.14% | -0.76% | 8.63% | 8.10% | 14.69% | 176.15% | 98.45% | 56.65% | 418.49% | 2,332.69% |
Ownership & Short Interest
Calculate Your Gland Pharma Investment Returns
Long-Term Investment Performance Analysis
Gland Pharma stock price in Nov 2020 was ₹1,819.55, A ₹1,000.00 lump sum investment in Gland Pharma made 5 years ago would be worth approximately ₹1,214.59 today, representing a positive return of 21.46%. This translates to an annualized return (CAGR) of 3.55%.
5 Years 6 Months Investment Scenario (Nov 2020 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is GLAND's 52-week high and low?
- In the last 52 weeks, Gland Pharma reached a high of ₹2,396.00 (on May 25, 2026) and a low of ₹1,573.60 (on March 16, 2026).
- What is the market cap and P/E ratio for GLAND?
- Curious about Gland Pharma's size and valuation? Its market capitalization stands at 295.80B. When it comes to valuation, the P/E ratio (trailing twelve months) is 34.86, and the forward P/E (looking ahead) is 25.03.
- Does GLAND pay dividends? If so, what's the yield?
- Yes, Gland Pharma is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 1.95%, and the company has paid an average of ₹12.67 per share annually over the past 3 years.
- Who are Gland Pharma's main competitors or similar companies to consider before investing?
When looking at Gland Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.88T Healthcare Drug Manufacturers - Specialty & Generic 7.10% 82.23% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic -0.43% 85.44% Torrent
TORNTPHARM1.39T Healthcare Drug Manufacturers - Specialty & Generic 40.54% 146.00% Dr. Reddy's
DRREDDY1.10T Healthcare Drug Manufacturers - Specialty & Generic -6.39% 29.74% Lupin
LUPIN1.07T Healthcare Drug Manufacturers - Specialty & Generic 14.69% 176.15% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Gland Pharma Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Gland Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 7.63%, the Debt to Equity ratio from the most recent quarter is 3.16, and its Gross Profit Margin stands at 65.99%.
- What is the recent revenue and earnings growth for GLAND?
- Looking at Gland Pharma's growth, its revenue over the trailing twelve months (TTM) was INR61B. Compared to the same quarter last year (YoY), quarterly revenue grew by 22.50%, and quarterly earnings saw a YoY growth of 27.70%.
- How much of GLAND stock is held by insiders and institutions?
- Wondering who owns Gland Pharma stock? Company insiders (like executives and directors) hold about 51.84% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 36.58%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.